Pyrosequencing analysis of KRAS codon 61 mutations in Thai patients with advanced colorectal cancer

Teerapakpinyo, Chinachote; Wanthong, Phanni; Aumchaaumchaya, Mathawee; Chankate, Piyamai; Kaikeaw, Warisa; Tosakorn, Warunya; Shaungshoti, Shanop

doi:10.5372/1905-7415.0901.369

References

Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol. 2009; 6:519-27.10.1038/nrclinonc.2009.11119636327
Open DOI Search in Google Scholar Back to article
Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2011; 30: 3570-7.
Search in Google Scholar Back to article
Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011; 50:307-12.2130564010.1002/gcc.20854
Open DOI Search in Google Scholar Back to article
Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Medicine. 2008; 358:1160-74.10.1056/NEJMra0707704
Open DOI Search in Google Scholar Back to article
Buhrman G, Wink G, Mattos C. Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf. Structure. 2007; 15:1618-29.10.1016/j.str.2007.10.01118073111
Open DOI Search in Google Scholar Back to article
Feig LA, Cooper GM. Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol Cell Biol. 1988; 8:2472-8.304317810.1128/MCB.8.6.2472
Open DOI Search in Google Scholar Back to article
Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Brit J Cancer. 2009; 101: 715-21.10.1038/sj.bjc.6605177
Open DOI Search in Google Scholar Back to article
Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009; 27:5931-7.1988454910.1200/JCO.2009.22.4295
Open DOI Search in Google Scholar Back to article
Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360:1408-17.10.1056/NEJMoa080501919339720
Open DOI Search in Google Scholar Back to article
Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012; 48:1466-75.2244602210.1016/j.ejca.2012.02.057
Open DOI Search in Google Scholar Back to article
Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, et al. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. Cancer Sci. 2013; 104: 473-80.2329831310.1111/cas.12098
Open DOI Search in Google Scholar Back to article
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med. 2004; 351: 337-45.10.1056/NEJMoa033025
Open DOI Search in Google Scholar Back to article
Wilson PM, Labonte MJ, Lenz HJ. Molecular markers in the treatment of metastatic colorectal cancer. Cancer J. 2010; 16:262-72.10.1097/PPO.0b013e3181e0773820526105
Open DOI Search in Google Scholar Back to article
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26: 5705-12.1900132010.1200/JCO.2008.18.0786
Open DOI Search in Google Scholar Back to article
Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol. 2009; 27:5924-30.10.1200/JCO.2008.21.679619884556
Open DOI Search in Google Scholar Back to article
Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009; 27:1477-84.1923763310.1200/JCO.2008.18.6544
Open DOI Search in Google Scholar Back to article
Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009; 20:84-90.18669866
Search in Google Scholar Back to article
Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009; 69:1851-7.10.1158/0008-5472.CAN-08-246619223544
Open DOI Search in Google Scholar Back to article
Hatzaki A, Razi E, Anagnostopoulou K, Iliadis K, Kodaxis A, Papaioannou D, et al. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients. Mol Cell Probes. 2001; 15:243-7.10.1006/mcpr.2001.036711735295
Open DOI Search in Google Scholar Back to article
Malapelle U, Bellevicine C, Salatiello M, de Luca C, Rispo E, Riccio P, et al. Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist’s perspective. J Clin Pathol. 2012; 65: 940-4.10.1136/jclinpath-2012-20077322872705
Open DOI Search in Google Scholar Back to article
Malapelle U, Carlomagno C, Salatiello M, De Stefano A, De Luca C, Bianco R, et al. KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Brit J Cancer. 2012; 107: 626-31.10.1038/bjc.2012.275
Open DOI Search in Google Scholar Back to article
Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, Fountzilas G, et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One. 2009; 4:e7746.1988847710.1371/journal.pone.0007746
Open DOI Search in Google Scholar Back to article
Morlan J, Baker J, Sinicropi D. Mutation detection by real-time PCR: a simple, robust and highly selective method. PLoS One. 2009; 4:e4584.10.1371/journal.pone.000458419240792
Open DOI Search in Google Scholar Back to article
Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005; 7:413-21.1604931410.1016/S1525-1578(10)60571-5
Open DOI Search in Google Scholar Back to article
Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A, Schneider-Stock R. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract. 2007; 203:489-97.1762941910.1016/j.prp.2007.06.001
Open DOI Search in Google Scholar Back to article
De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304:1812-20.2097825910.1001/jama.2010.1535
Open DOI Search in Google Scholar Back to article

Pyrosequencing analysis of KRAS codon 61 mutations in Thai patients with advanced colorectal cancer

References

Paradigm

My account